生物医药作为战略性新兴产业，近来在浙江发展势头迅猛。根据杭州海关统计，2012年1-7月，在其他产品出口趋缓的形势下，浙江省出口生物医药（包括天然或合成再制的激素、抗血清、疫苗、毒素、培养微生物等）达到1.6亿美元，比去年同期增长26.2%，增速高出去年同期14.7个百分点。

Biological medicine as a strategic emerging industry,Recently in zhejiang fast development situation.According to hangzhou customs statistics,2012 1 - July,In other products export muted situation,Zhejiang export biological medicine(Including natural or synthetic remake of the hormone/antiserum/vaccine/toxin/Cultured microorganisms, etc)Us $160 million,Than last year the corresponding period grows 26.2%,Higher than the same period last year growth of 14.7%.

　　新药出口增多

Drugs increased export

　　海关提供上门服务

The customs to provide door-to-door service

　　“这样的增速，表明我们浙江的生物医药产业势头很好。”浙江贝达药业销售经理吴先生告诉记者，近年来浙江药企对研发的投入普遍加大，

"Such growth,Show that we, zhejiang biological medicine industry momentum is very good."Zhejiang beida pharmaceutical sales manager Mr. Wu told reporters,In recent years, zhejiang medicine enterprises to r&d investment generally increase,

　　浙江华海药业(600521,股吧)有限公司是台州最大的医药出口企业，近年来企业一直致力于实施产品从原料药到高利润的仿制药（制剂）的转型升级。

Zhejiang huahai pharmaceutical(600521,guba)Co., LTD. Is the largest taizhou medicine export enterprise,In recent years, the enterprise has been committed to the implementation of product from apis to highly profitable generics(preparation)Transformation and upgrading of the.

　　该企业年初预计，2012制剂出口收入将突破1.5亿元,将进入国内制剂出口前10名(含合资企业) 。

At the beginning of this enterprise is expected,2012 preparation export revenues will exceed 150 million yuan,Will enter the domestic export preparation before 10(Including joint venture) .

　　“随着研发能力的逐渐强大，我们出口的很多是新药，国家没有具体列明的到底该报哪个税号。”华海药业的单证员小吴说起新药出口时的“困惑”。

"With the research and development ability strong gradually,We export many are new drugs,Countries are not specified exactly the newspaper which grows."Huahai pharmaceutical documents clerk xiao wu speaking of new drug of export"confused".

　　不过，为帮助企业顺利走出国门，台州海关启动大企业联络员制度，专门安排一名精通业务的骨干为该公司联络员，在新药的研发阶段，联络员就提前介入提供归类帮助，对一些特别复杂的药品，提前向上级海关申请明确，确保企业不因归类疑难延误出口。

but,In order to help enterprise smooth out of the country,Taizhou customs start big business liaison staff system,Specially arranged for a proficient in the backbone of the business for the company liaison man,In the new drug research and development stage,Liaison staff in advance to provide help in classification,For some special complex drugs,Advance to superior customs application clear,Ensure enterprise not by the classification difficult delay export.

　　华海药业董事长陈保华说：“仿制药我们在做，印度、东南亚企业也在做，就比谁做得快，出得快，所以走出国门打通一条快速通道尤其重要。”今年1-7月份，华海药业出口达1.3亿美元，同比大幅增长35.1%。

Huahai pharmaceutical chairman ChenBaoHua said:"Generics we are doing,India/Southeast Asia enterprise also doing,Than who do quickly,A fast,So go out of the country through a fast channel is especially important."This year in July 1 -,Huahai pharmaceutical exports were worth $130 million,35.1% year-on-year growth.

　　外商投资企业

Enterprises with foreign investment

　　出口占半壁江山

Exports deodorants

　　浙江的医药企业发展迅速，也得益于与外商的合作。根据统计，今年1-7月，浙江省外商投资企业出口生物医药8759万美元，增长18.3%，占同期全省生物医药出口总值的55.6%，占据了半壁江山。其中，外商独资企业出口5068万美元，增长11.7%，占32.2%。

Zhejiang pharmaceutical enterprise developing rapidly,Also benefit from and foreign cooperation.According to statistics,This year on July 1 -,Zhejiang foreign investment enterprises to export biological medicine $87.59 million,Growth of 18.3%,The same period of the biological medicine export 55.6% of the total,Occupied deodorants.the,Wholly foreign-owned enterprises to export 50.68 million dollars,Growth of 11.7%,Accounted for 32.2%.

　　浙江药企与国际企业的合作也显现出优势。2011年6月海正药业(600267,股吧)与辉瑞制药牵手，令其对制剂出口有了更多的“国际”筹码。根据海正药业介绍，之前海正与外资的合作，大多是生产针对国际市场的药品，基本采用代工等方式；然而，从携手辉瑞开始，海正不断加大研发投入，更为清晰地挑明了向自主制剂转型的决心和信心。

Zhejiang medicine enterprises and international enterprise cooperation also show advantage.June 2011 sea are pharmaceutical(600267,guba)And Pfizer pharmaceutical in hand,Make the preparation export have more"international"chip.According to the sea are pharmaceutical is introduced,The sea is before with foreign cooperation,Mostly production according to the international market drug,The basic way of OEM;however,From Pfizer began to hand in hand,The sea is constantly increasing r&d investment,More clearly TiaoMing to independent preparation transformation of the determination and confidence.

　　9月5日，浙江海正药业董事会发公告，其分公司海正杭州公司“注射剂国际化发展能力建设项目”和“年产320万支抗体药物安佰诺产业化与国际化能力建设项目”已被列入国家战略性新兴产业发展专项资金计划，分别获国家补助资金人民币4000万元和5000万元，合计9000万元。

On September 5,,Zhejiang sea are the board of directors of the pharmaceutical send announcement,The sea is hangzhou branch company"Injection internationalization development ability construction project"and"With an annual capacity of 3.2 million branch antibody drug Ann hundred's industrialization and internationalization ability construction project"Have been listed in the national strategic emerging industry development special funds plan,Respectively in state aid capital of RMB 40 million yuan and 50 million yuan,Total 90 million yuan.

　　“浙江的生物医药主要出口欧盟和美国，对非洲出口增长较快。1-7月，浙江省对欧盟出口生物医药4713万美元，增长31.3%；对美国出口3345万美元，增长32.6%；两者合计占同期全省生物医药出口总值的51.1%。而对非洲出口生物医药1721万美元，增长达70.4%。”杭州海关相关负责人说，除了向国外出口新药品，值得关注的是，浙江的中药材及中式成药出口速度增长也很快。1-7月，浙江省出口中药材及中式成药683.4万美元，增长80%。

"Zhejiang's biological medicine are mainly exported to the European Union and the United States,Rapid export growth in Africa.1 - July,Zhejiang province exports to Europe biological medicine $47.13 million,Growth of 31.3%;Exports to the us $33.45 million,Growth of 32.6%;Together the same period of the biological medicine export 51.1% of the total.In Africa and export biological medicine $17.21 million,Growth of 70.4%."Hangzhou customs related person in charge said,In addition to export to abroad new drugs,There is concern,Zhejiang's Chinese herbal medicine and Chinese medicine export speed growth also soon.1 - July,Zhejiang export Chinese herbal medicine and Chinese medicine 6.834 million dollars,Growth of 80%.